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Background:  Transforming growth factor beta receptors (T`Rs) play important roles in vascular biology through their regulation of Smad 
transcription factors. Loss of signaling by the bone morphogenetic protein type II receptor (BMPR-II), a type II T`R, is associated with development of 
pulmonary arterial hypertension (PAH). The aim of this study was to determine the role of `-arrestins (`arr1 and 2), versatile adapter proteins that 
regulate signaling by a number of transmembrane receptors, in the regulation of BMPR-II signaling.
Results:  We found that BMPR-II interacts with `arrs in response to ligand stimulation with BMPs as assessed by translocation of fluorescently 
labeled `arr2 in transiently transfected HEK293 cells and by co-immunoprecipitation at endogenous levels in human pulmonary artery smooth 
muscle cells (PASMCs). In PASMCs, siRNA knockdown of`arr1 significantly inhibited Smad 1/5/8 phosphorylation at late time points after 
stimulation with BMP4 (WT 6.0 ± 1.6 , `arr1 KO 1.8 ± 0.3 fold, p < 0.05), while knockdown of `arr2 significantly increased phosphorylation at early 
time points (WT 0.7 ± 0.1, `arr2 KO 1.5 ± 0.3 fold, p < 0.05). To assess the relevance of these effects to the development of PAH, we subjected 
wild type (WT),`arr1 and 2 knockout (KO) mice to 4 weeks of chronic hypoxia (10% FiO2). Mirroring the biochemical phenotype, `arr1 KO mice 
behaved like loss-of-function BMPR-II mutants, developing significantly higher RV pressures and hypertrophy with significantly lower RV fractional 
shortening. Conversely, `arr2 KO mice were relatively protected against hypoxia-induced pulmonary hypertension with less RV hypertrophy and 
higher RV fractional shortening (Fractional shortening: WT 0.14 ± 0.02, `arr1 KO 0.06 ± 0.02,`arr2 KO 0.29 ± 0.02, p < 0.05). Real time PCR of 
the lungs from both `arr KO mice demonstrated significant differences in the induction of genes regulated by BMPR-II.
Conclusions:  `arrs regulate BMPR-II signaling through Smads and their transcriptional targets, altering susceptibility to the development of PAH. 
Regulation of canonical T`R signaling to Smads by`arrs is a novel mechanism and may have implications for the development of therapeutics for 
PAH.
